X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
IDE397 is a potential first-in-class small molecule MAT2A inhibitor, which is being evaluated in combination with Trodelvy for the treatment of MTAP-deletion bladder cancer.
Lead Product(s): IDE397,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: IDE397
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Details:
Company announced Phase 3 study of Trodelvy® (sacituzumab govitecan, ADC) in combination with chemotherapy in locally advanced or metastatic urothelial cancer.
Lead Product(s): Sacituzumab Govitecan,Paclitaxel,Docetaxel
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Details:
The collaboration aims to evaluate the safety and efficacy of Debio 0123, Debiopharm's investigational, potential best-in-class WEE1 inhibitor, together with Trodelvy (sacituzumab govitecan).
Lead Product(s): Debio 0123,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 28, 2024
Details:
Cosela (trilaciclib) CDK4/CDK6 inhibitor is being evaluated in combination with a TROP2 ADC sacituzumab govitecan for the treatment of Triple Negative Breast Cancer.
Lead Product(s): Trilaciclib,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2024
Details:
The financing aims to support the company in the clinical development of Trodelvy (sacituzumab govitecan), rop-2 directed antibody-drug conjugate. It is being evaluated for the treatment of Non-Small Cell Lung Cancer.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Abingworth
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 29, 2024
Details:
The collaboration is designed to evaluate and combine DF1001, which is a new molecule that targets natural killer cells and T-cell activation signals, with Gilead's Trop-2-directed antibody-drug conjugate in the treatment of metastatic breast and non-small cell lung cancer.
Lead Product(s): Df1001,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: DF1001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2024
Details:
Trodelvy (sacituzumab govitecan-hziy) is the first approved Trop-2-directed antibody-drug conjugate which is under phase 3 clinical trials for the treatment of metastatic or advanced Non-Small Cell Lung Cancer.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate, approved for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
The data highlight the potential for G1T28 (trilaciclib) to meaningfully reduce adverse events related to use of sacituzumab. As expected, patients with PD-L1(+) tumors appear to respond earlier than patients with PD-L1(-) tumors.
Lead Product(s): Trilaciclib,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
The investment will facilitate the creation of a cross-industry synergistic environment for the development and production of ADC platforms including, PINOT-ADC™, a next-generation ADC anti-cancer drug platform developing PBX-001 (sacituzumab), targeting solid cancer Trop2.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: PBX-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lotte Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 21, 2023
Details:
Under the agreement, Everest Medicines will transfer all development and commercialization rights to Gilead for Trodelvy® (sacituzumab govitecan), a first-in-class Trop-2 directed antibody-drug conjugate, in Greater China and South Korea, among Other Asian Markets.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immunomedics
Deal Size: $455.0 million Upfront Cash: $280.0 million
Deal Type: Acquisition March 26, 2023
Details:
Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers.
Lead Product(s): Sacituzumab Govitecan,Pembrolizumab
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
Trodelvy® (sacituzumab govitecan-hziy) is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
Details:
Under the terms of collaboration, Gilead will supply TRODELVY (sacituzumab govitecan-hziy) for prospective, pan-tumor trial. Trodelvy is an antibody-drug conjugate immune targeted therapy indicated for unresectable locally advanced or metastatic triple- negative breast cancer.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2023
Details:
Trodelvy (Sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
Trilaciclib (Cosela), is well tolerated when administered prior to sacituzumab. Initial data on the first 18 patients show a effect of trilaciclib to reduce (>50%) the rates of multiple adverse events compared to the sacituzumab govitecan-hziy single agent safety profile.
Lead Product(s): Trilaciclib,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate, is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
In study, Trodelvy (sacituzumab govitecan-Hziy) demonstrated statistically significant and clinically meaningful improvement of 3.2 months in OS compared to TPC (median OS: 14.4 months vs. 11.2 months; hazard ratio =0.79; OS was key secondary endpoint of trial.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Analysis examined progression-free survival in intention-to-treat population by HER2-immunohistochemistry (IHC) status, and results demonstrated that Trodelvy (sacituzumab govitecan) improved median PFS vs. TPC in both HER2-low (IHC1+ and IHC2+/ISH-negative) and IHC0 groups.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2022
Details:
Highlights include a late-breaking presentation of the secondary endpoint of overall survival from the Phase 3 TROPiCS-02 study investigating Trodelvy® (sacituzumab govitecan-hziy) in people with pre-treated HR+/HER2- metastatic breast cancer.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
Under the terms of the agreement, Gilead will also have the opportunity to recruit Everest employees working directly on the Trodelvy program. Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $455.0 million Upfront Cash: $280.0 million
Deal Type: Acquisition August 15, 2022
Details:
Trodelvy® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
Trodelvy (Sacituzumab Govitecan-Hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
In follow-up analysis from final database lock, Trodelvy (Sacituzumab Govitecan-hziy) improved median PFS versus physicians’ choice of chemotherapy and extended median overall survival by almost five months in intent-to-treat population.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Trodelvy (sacituzumab govitecan), is a first-in-class Trop-2 directed antibody-drug conjugate , is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Everest Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
Study for Trodelvy (Sacituzumab Govitecan-hziy) met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
In single-arm Phase 2 study, Trodelvy demonstrated an ORR of 33.3 percent and a median DoR of 7.7 months, as determined by local assessment, in 108 adult TNBC patients who had previously received a median of three prior systemic therapies in the metastatic setting.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
Sacituzumab govitecan (SG) is a first-in-class Trop-2 directed antibody-drug conjugate, is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
Trodelvy (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate, demonstrated consistent activity in breast cancer patient also, met its primary endpoint with a statistically significant improvement in PFS versus physician’s choice of chemotherapy.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
A combination of Trodelvy (Sacituzumab govitecan) with an immune-stimulating agent KEYTRUDA could potentially provide a new treatment option for a broader set of patients with first-line metastatic NSCLC is now undergoing Phase 3 clinical trial.
Lead Product(s): Sacituzumab Govitecan,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: MSD
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
As part of the collaboration, Merck will sponsor a global Phase 3 clinical trial of Trodelvy in combination with KEYTRUDA as a first-line treatment for patients with metastatic NSCLC.
Lead Product(s): Sacituzumab Govitecan,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2022
Details:
New data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan) topoisomerase inhibitor in relapsed or refractory metastatic triple-negative breast cancer received two or more prior systemic therapies, at least one of them for metastatic disease.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2021
Details:
Trodelvy first-in-class antibody and topoisomerase inhibitor conjugate directed to the Trop-2 receptor, a protein overexpressed in multiple types of epithelial tumors, including metastatic TNBC and metastatic urothelial cancer.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2021
Details:
Sacituzumab govitecan is approved first-in-class antibody and topoisomerase inhibitor conjugate directed to the Trop-2 receptor, a protein overexpressed in multiple types of epithelial tumors, including metastatic TNBC and metastatic urothelial cancer (UC).
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2021
Details:
These data highlight the value of Trodelvy in treating people with metastatic triple-negative breast cancer (TNBC) and Gilead’s transformative science in cancers with high unmet need.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2021
Details:
Sacituzumab govitecan-hziy (SG) is a first-in-class antibody and topoisomerase inhibitor conjugate directed at TROP-2, a protein frequently expressed in multiple types of epithelial cancers. SG is approved in the United States under the trade name Trodelvy ®.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2021
Details:
Anktiva and PD-L1 t-haNK when used in combination with Trodelvy may show additive or even synergistic effects, greatly increasing the response rate and, importantly, durability of responses.
Lead Product(s): N-803,PD-L1 t-haNK,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
Sacituzumab govitecan-hziy (SG) is a first-in-class, antibody-drug conjugate (ADC) directed at TROP-2, a membrane antigen that is over-expressed in many common epithelial cancers. SG is approved in the United States under the trade name Trodelvy ®.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
NEJM publication of the positive data from the Phase 3 ASCENT study demonstrated that Trodelvy significantly extended both progression-free survival and overall survival for patients, compared to standard single-agent chemotherapy.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2021
Details:
U.S. FDA has granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer who have previously got a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
Details:
The Phase 2 single arm, multiple-cohorts basket trial will evaluate sacituzumab govitecan-hziy in 180 patients with relapse/refractory esophageal squamous cell carcinoma, gastric cancer, and cervical cancer at selected sites in China.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Details:
This milestone marks the first of a series of planned NDA submissions for sacituzumab govitecan-hziy in Everest’s licensed territory, which also includes Greater China, South Korea, and certain additional Southeast Asian countries/regions.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
Details:
Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate that is indicated in the U.S. for the treatment of adult patients with mTNBC who have received at least two prior therapies for metastatic disease.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
EVER-132-002 is a Phase 3 Asian study designed to assess and compare the efficacy and safety of sacituzumab govitecan versus TPC in Asian patients with HR+/HER2- mBC who received at least two, and no more than four systemic chemotherapy regimens.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
EVER-132-001 is a single-arm, multi-center Phase 2b registration clinical trial that is designed to evaluate the efficacy and safety of sacituzumab govitecan in Chinese patients with mTNBC who have received at least two prior systemic chemotherapy regimens.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
NMPA of the People’s Republic of China has approved a CTA for Trodelvy ™ for the treatment of patients with hormone receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer who have failed at least two prior chemotherapy regimens.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2020
Details:
Gilead gains Trodelvy, Immunomedics' lead ADC, is the first ADC the FDA has approved for the treatment of people with metastatic triple-negative breast cancer and is also the first FDA-approved anti-Trop-2 ADC.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $21,000.0 million Upfront Cash: $15,000.0 million
Deal Type: Acquisition October 23, 2020
Details:
Trodelvy has shown encouraging activity in an early-stage study in brain cancers, including partial responses in small cohorts of patients with brain metastasis from breast cancer and recurrent glioblastoma.
Lead Product(s): Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Trodelvy
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
